Affordable AMS Accium positions its DirectAMS program and cost-efficient AMS services as a competitive differentiator, presenting a potential upsell path to customers at larger pharma firms seeking high-sensitivity 14C measurements with controlled costs.

Top-Tier Clients With five of the top ten global pharma companies using Accium’s services, there is an opportunity to expand relationships within these accounts through broader service mix, increased throughput, or expanded PK, metabolism and mass balance capabilities.

Integrated Services The ability to mix and match AMS, Bioanalytical and Quality services creates a cross-sell opportunity to offer end-to-end outsourcing for drug development workflows, reducing vendor fragmentation for customers.

Global Access As the first commercial AMS facility in North America launched in 2006, Accium has established credibility and could target mid-market biotech and regional sponsors seeking accessible high-sensitivity analytics with rapid turnaround.

Growth Readiness With a lean team and revenue in the low-to-mid millions, there is potential to expand capacity, improve service levels, and pursue larger contract sizes or repeat business from existing pharma customers looking to scale studies.